Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The race to find an effective treatment for coronavirus disease 2019 (COVID-19) is still on, with only two treatment options currently authorized for emergency use and/or recommended for patients hospitalized with severe respiratory symptoms: low-dose dexamethasone and remdesivir. The USA decision to stockpile the latter has resulted in widespread condemnation and in similar action being taken by some other countries. In this commentary we discuss whether stockpiling remdesivir is justified in light of the currently available evidence.

Original publication




Journal article


J Comp Eff Res

Publication Date





1243 - 1246


COVID-19, SARS-CoV-2, antiviral, coronavirus, dexamethasone, remdesivir, stockpiling, Adenosine Monophosphate, Alanine, Antiviral Agents, Humans, International Cooperation, Internationality, SARS-CoV-2, Strategic Stockpile, United States, COVID-19 Drug Treatment